Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function

Journal of Endocrinological Investigation

Volumn 32, Issue 5, 2009, Pages 435-439

  Ozkaya, M ^a   Sahin, M ^b   Cakal, E ^c   Yuzbasioglu, F ^a   Sezer, K ^d   Kilinc, M ^a   Simsek Imrek, S ^a  

^a Maras Sutcuimam School of Medicine   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^d MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antithyroid therapy; Hyperthyroidism; Hypothyroidism; L thyroxine; Visfatin

Indexed keywords

DELTA VISFATIN; LIOTHYRONINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; THYROID FUNCTION TEST;

ADULT; ANTITHYROID AGENTS; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSMOLAR CONCENTRATION; PROPRANOLOL; PROPYLTHIOURACIL; RECOVERY OF FUNCTION; THYROID GLAND; THYROXINE;

EID: 70350336255     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.3275/6296     Document Type: Article

References (29)

1. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. nt J Obes Relat Metab Disord 2000, 24 (Suppl 2): S109-12.
2. Duntas LH. Thyroid disease and lipids. Thyroid 2002, 12: 287-293
3. Iglesias P, Díez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007, 40: 61-70. (Pubitemid 350180533)
4. Dimitriadis GD, Raptis SA. Thyroid hormone excess and glucose intolerance. Exp Clin Endocrinol Diabetes 2001, 109 (Suppl 2): S225-39.
5. Pontikides N, Krassas GE. Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid 2007, 17: 421-431 (Pubitemid 46878845)
6. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91: 295-299
7. Varma V, Yao-Borengasser A, Rasouli N, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007, 92: 666-672 (Pubitemid 46255312)
8. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54: 2911-2916 (Pubitemid 41401086)
9. Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007, 30: 1278-1280 (Pubitemid 46684663)
10. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes. Metabolism 2007, 56: 451-458 (Pubitemid 46427838)
11. Teoh H, Lovren F, Verma S. Vascular dysfunction: a Janus face of visfatin in diabetes? Metabolism 2007, 56: 459-461
12. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007, 56: 1216-1220
13. Iglesias P, Alvarez Fidalgo P, Codoceo R, Díez JJ. Plasma concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003, 59: 621-629 (Pubitemid 37357624)
14. Pilz S, Mangge H, Obermayer-Pietsch B, März W. Visfatin/pre-B-cell colony-enhancing factor a protein with various suggested functions. J Endocrinol Invest 2007 Feb, 30: 138-144 (Pubitemid 46614445)
15. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307: 426-430 (Pubitemid 40139988)
16. Samara A, Pfister M, Marie B, Visvikis-Siest S. Visfatin, low-grade inflammation and body mass index (BMI). Clin Endocrinol (Oxf) 2008, 69: 568-574
17. MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 2007, 9: 490-497 (Pubitemid 47018512)
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from plasma glucose and insulin concentrations in man. Diabetologia 28, 1985: 412-419 (Pubitemid 15018832)
20. Arrigo T, Wasniewska M, Crisafulli G, et al. Subclinical hypothyroidism: the state of the art. J Endocrinol Invest 2008, 31: 79-84.
21. Samal B, Sun Y, Steams G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol 1994, 14: 1431-1437 (Pubitemid 24984261)
22. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Müller M, Wolzt M. Exercise training lowers Plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 2006, 91: 4702-4704 (Pubitemid 44833460)
23. Celik I, Akalin S, Erbas T. Serum levels of interleukin-6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995, 132: 668-672
24. Komorowski J, Jankiewicz J, Robak T, Błasinska-Morawiec M, Stepien H. Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunol Lett 1998, 60: 143-148 (Pubitemid 28157258)
25. Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000, 143: 197-202. (Pubitemid 30622353)
26. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005, 289: E586-90. (Pubitemid 41356079)
27. Barzilai N, Cohen P, Barzilai D, Karnieli E. Increased insulin responsiveness and insulin clearance in thyrotoxicosis. Isr J Med Sci 1985, 21: 722-726 (Pubitemid 16256422)
28. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008, 69: 878-884
29. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. Clin Endocrinol Metab 2007, 92: 4783-4791 (Pubitemid 350223461)